Alpha Zero’s BioXcel Therapeutics BTAI Stock Holding History

Alpha Zero’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,272	Closed	-$19.6K	–	62
2024 Q4	$19.6K	Buy	+3,272	New	+$27.3K	0.01%	71

Other funds holding BTAI

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Alpha Zero's BTAI Position: Q1 2025 in Review

Alpha Zero sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 3,272 shares — an estimated $19.6K sold.

Alpha Zero first reported a position in BTAI in Q4 2024 and held it in 1 quarter. The position peaked at $19.6K in Q4 2024. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

Alpha Zero reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
Alpha Zero sold 3,272 BioXcel Therapeutics shares in Q1 2025, an estimated $19.6K.
Alpha Zero first reported a position in BioXcel Therapeutics in Q4 2024 and held it in 1 quarter.
Alpha Zero's BioXcel Therapeutics position peaked at $19.6K in Q4 2024.
31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Alpha Zero's 13F filing for Q1 2025, filed 12 Nov 2025.